US Stock MarketDetailed Quotes
ACAD ACADIA Pharmaceuticals
- 16.350
- -0.560-3.31%
Trading Dec 19 10:02 ET
2.72BMarket Cap20.96P/E (TTM)
17.210High16.270Low121.59KVolume17.000Open16.910Pre Close2.02MTurnover0.11%Turnover RatioLossP/E (Static)166.39MShares31.93052wk High4.71P/B1.78BFloat Cap14.15052wk Low--Dividend TTM108.95MShs Float58.720Historical High--Div YieldTTM5.56%Amplitude0.650Historical Low16.576Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
ACADIA Pharmaceuticals Stock Forum
ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...
Oracle ( $Oracle (ORCL.US)$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals (ACAD.US)$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts (MTN.US)$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana (ASAN.US)$ Asana rep...
No comment yet